Infliximab Risk Evaluation and Mitigation Strategy: Embarking and Executing on the New Era in Drug Safety

Time

Tue, Jun 26 11:00AM
T 16

Title

Infliximab Risk Evaluation and Mitigation Strategy: Embarking and Executing on the New Era in Drug Safety

Abstract Summary

The FDA may require drug manufacturers to implement a REMS, if they determine that a REMS is necessary to ensure that the benefits of the drug or biological product outweigh the risks of the medication.

Poster Presenter

Brenda Sarokhan
MPH,
Sr. Director, REMS,
Johnson and Johnson
United States

© 2015 DIA